IsoPlexis (IsoPlexis) EBIT : $-100.65 Mil (TTM As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis EBIT?

IsoPlexis's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was $-31.55 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was $-100.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IsoPlexis's annualized ROC % for the quarter that ended in Dec. 2022 was -186.67%. IsoPlexis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -293.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IsoPlexis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -226.20%.

IsoPlexis EBIT Historical Data

The historical data trend for IsoPlexis's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis EBIT Chart

IsoPlexis Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EBIT

-13.63

-23.25

-77.95

-100.66

IsoPlexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT	Get a 7-Day Free Trial								-24.32	-27.74	-24.40	-16.97	-31.55

Competitive Comparison of IsoPlexis's EBIT

For the Medical Devices subindustry, IsoPlexis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IsoPlexis's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IsoPlexis's EV-to-EBIT falls into.

IsoPlexis EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.65 Mil.

IsoPlexis (NAS:ISO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IsoPlexis's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

	ROC % (Q: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2022 )	+	Invested Capital (Q: Dec. 2022 ))	/ count )
=	-126.82 * ( 1 - 0% )	/	( (75.777	+	60.097)	/ 2 )
=	-126.82	/	67.937
=	-186.67 %

where

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	134.852	-	5.947	-	( 53.128	-	max(0, 11.216	-	97.623	+	53.128	))
=	75.777

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	109.068	-	11.506	-	( 37.465	-	max(0, 17.711	-	71.865	+	37.465	))
=	60.097

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

IsoPlexis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2022		Q: Dec. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-126.196	/	( ( (16.712 + max(34.84, 0))	+	(16.305 + max(18.277, 0)) )	/	2 )
=	-126.196	/	( ( 51.552	+	34.582 )	/	2 )
=	-126.196	/	43.067
=	-293.02 %

where Working Capital is:

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.569	+	38.247	+	1.679)	-	(5.947	+	1.034	+	2.674)
=	34.84

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.502	+	27.516	+	2.382)	-	(11.506	+	1.434	+	3.183)
=	18.277

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IsoPlexis's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2022 )
	=	-100.654	/	44.497
	=	-226.20 %

IsoPlexis EBIT Related Terms

Thank you for viewing the detailed overview of IsoPlexis's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 North East Industrial Road, Branford, CT, USA, 06405

Website

https://www.isoplexis.com

IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley	officer: Chief Financial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay	director, officer: Chief Executive Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii	officer: SVP, GC & Secretary	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath	director	C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm	director	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers	director	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley	director	396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho	director, 10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel	officer: Chief Commercial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou	officer: Chief Scientific Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar	officer: VP, Finance	35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc	10 percent owner	4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003